The patent was assigned to Elan Pharma International and is exclusively licensed to Jazz Pharmaceuticals in the US through a product licensing agreement with Solvay Pharmaceuticals.
The patent claims the formulation incorporating Elan’s Sodas (Spheroidal Oral Drug Absorption System) technology, as well as a method of using the formulation for the treatment of obsessive compulsive disorder (OCD).
Luvox CR was previously approved by the FDA for the treatment of social anxiety disorder and OCD in adults. The patent has been listed for Luvox CR in the FDA Orange Book.